HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02142 HBM HOLDINGS-B

Closed 08-14 16:08:36

15.100

-0.710

-4.49%

High16.000	Low14.990	Vol4.42M
Open15.810	D1 Closing15.810	Amplitude6.39%
Mkt Cap13.12B	Tradable Cap13.12B	Total Shares869.00M
T/O67.30M	T/O Rate0.51%	Tradable Shares869.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02142","market":"HK","secType":"STK","nameCN":"HBM HOLDINGS-B","latestPrice":15.1,"timestamp":1786694916003,"preClose":15.81,"halted":0,"volume":4419544,"delay":0,"changeRate":-0.04490828589500322,"floatShares":869000000,"shares":869000000,"eps":0.8631648330953091,"marketStatus":"Closed","change":-0.71,"latestTime":"08-14 16:08:36","open":15.81,"high":16,"low":14.99,"amount":67300450,"amplitude":0.063884,"askPrice":15.1,"askSize":25000,"bidPrice":15.02,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.863156986142281,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":5,"adr":0,"listingDate":1607529600000,"exchange":"SEHK","adjPreClose":15.81,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.39326,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02142/tweets","defaultTab":"tweets","newsList":[{"id":"2658206672","title":"HBM Holdings (SEHK:2142) Names Metabolic Chief And Partners With Sinopharm, Is It Fully Priced?","url":"https://stock-news.laohu8.com/highlight/detail?id=2658206672","media":"Simply Wall St.","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658206672?lang=en_us&edition=fundamental","pubTime":"2026-08-09 18:36","pubTimestamp":1786271810,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) has drawn fresh attention after Harbour BioMed announced two company level developments. Investors are weighing the appointment of a new president for its metabolic franchise and a collaboration with China National Pharmaceutical Group.\nSee our latest analysis for HBM Holdings.\nAt a share price of HK$14.19, HBM Holdings has seen strong recent momentum, with a 21.8% 1 month share price return and a 17.5% year to date share price return, while the 3 year total...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-names-metabolic-chief-and-partners-wit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/hbm-holdings-sehk2142-names-metabolic-chief-and-partners-wit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1583","MUD","MUZ","HBMX","DCF","VOTE","PMDE","BK4588","HBM","MIC","DECU","BK1574","DISK","DRMP","RAM","DRAL","RGLO","JOYT","GXDW","BK1161","MUU","02142","COPP","BK4168","VGFPF","DRMY","DRAM","MUYY","MULL","FEBU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121496757","title":"Hong Kong Stock Movers: HBM Holdings-B Surges Over 7% in Early Trading on First-Half Revenue Growth and Profitability, Following Strategic Partnership with Sinopharm","url":"https://stock-news.laohu8.com/highlight/detail?id=1121496757","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121496757?lang=en_us&edition=fundamental","pubTime":"2026-08-07 10:52","pubTimestamp":1786071136,"startTime":"0","endTime":"0","summary":"HBM Holdings-B (02142) saw its shares jump more than 7% in early trading on the Hong Kong Stock Exchange. As of the time of writing, the stock was up 7.23% at HK$13.65, with a trading volume of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4588","VXUS","BK4585","BK1161","02142","BK1574","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194490895","title":"HBM Holdings Adds 0.80 Million Shares from Option Exercises, Lifting Total Issued to 900.98 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1194490895","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194490895?lang=en_us&edition=fundamental","pubTime":"2026-08-06 23:04","pubTimestamp":1786028691,"startTime":"0","endTime":"0","summary":"HBM Holdings Limited reported that 800,800 new ordinary shares were issued in July 2026 through its Post-IPO Share Option Scheme, generating HKD 2.30 million in proceeds. The issuance expanded the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685915","title":"Harbour BioMed Names Bob Zhang President of Metabolic Disease Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685915","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657685915?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:11","pubTimestamp":1786003917,"startTime":"0","endTime":"0","summary":"Harbour BioMed names Bob Zhang president of metabolic disease franchiseHBM Holdings appointed Dr. Bob Zhang president of its metabolic disease franchise on Aug. 6, 2026; he will be based in Shanghai.Z","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLbRyCvg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657685991","title":"Harbour Biomed Appoints DR. Bob Zhang as President of Metabolic Disease Franchise to Accelerate Global Development of Innovative Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657685991","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657685991?lang=en_us&edition=fundamental","pubTime":"2026-08-06 16:11","pubTimestamp":1786003868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA2HCZ3Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK1574","BK1583","02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655887547","title":"Is HBM Holdings (SEHK:2142) Undervalued As Its Sinopharm Biologic Drug Consortium Takes Shape?","url":"https://stock-news.laohu8.com/highlight/detail?id=2655887547","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655887547?lang=en_us&edition=fundamental","pubTime":"2026-07-29 02:22","pubTimestamp":1785262928,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is back in focus after Harbour BioMed agreed to form the Sinopharm Harbour BioMed Innovation Consortium with China National Pharmaceutical Group, centered on research and development of biologic drugs.\nSee our latest analysis for HBM Holdings.\nAgainst this backdrop, HBM Holdings has been volatile, with the share price falling 1.74% over the past day but posting a 23.26% 1 month share price return. The 3 year total shareholder return is very large, signalling strong...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-undervalued-as-its-sinopharm-biolog","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MUU","BK4588","BK4168","DRMY","DRMP","DRAL","MUD","RAM","MUZ","DRAM","MIC","HBM","MULL","DCF","HBMX","BK1574","MUYY","02142","DISK","BK1583","BK1161","COPP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148016584","title":"HBM Holdings-B (02142) Forms Strategic Alliance with China National Pharmaceutical Group to Establish Joint Innovation Body","url":"https://stock-news.laohu8.com/highlight/detail?id=1148016584","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148016584?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:09","pubTimestamp":1785143347,"startTime":"0","endTime":"0","summary":"HBM Holdings-B (02142) has announced the signing of a strategic cooperation agreement with China National Pharmaceutical Group (Sinopharm) to create the Sinopharm-HBM Innovation Consortium. This...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","02142","BK1583","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654158090","title":"Harbour Biomed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D Consortium","url":"https://stock-news.laohu8.com/highlight/detail?id=2654158090","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654158090?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:02","pubTimestamp":1785142974,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA1TH9SF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02142","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654015810","title":"Hbm Holdings - Enters Strategic Collaboration with China National Pharmaceutical Group on Biologics R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015810","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654015810?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:01","pubTimestamp":1785142888,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43S02E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","02142","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654015861","title":"HBM Holdings Enters Strategic Biologics R&D Collaboration with Sinopharm","url":"https://stock-news.laohu8.com/highlight/detail?id=2654015861","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654015861?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:00","pubTimestamp":1785142856,"startTime":"0","endTime":"0","summary":"HBM Holdings enters strategic biologics R&D collaboration with SinopharmHBM Holdings entered a strategic collaboration with Sinopharm to form the Sinopharm–Harbour BioMed Innovation Consortium for inn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL8cR5Rm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653170167","title":"HBM Holdings Expects H1 Profit of Up to $67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653170167","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653170167?lang=en_us&edition=fundamental","pubTime":"2026-07-24 14:54","pubTimestamp":1784876092,"startTime":"0","endTime":"0","summary":"HBM Holdings  expects to post a profit of $62 million to $67 million for the first half of 2026, according to a Friday Hong Kong bourse filing.The company expects first-half revenue to increase to $120 million to $125 million from $101 million a year earlier.HBM attributed the expected growth to continued tie-ups with multinational pharmaceutical companies, including its long-term partnership with AstraZeneca and global collaboration with Bristol Myers Squibb.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MULL","RAM","02142","MUD","DISK","BK1583","HBMX","BK4588","DRMY","MIC","MUU","MUZ","DRMP","MUYY","DRAM","BK1161","DRAL","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653770324","title":"HBM Holdings Expects HY Revenue $120 Million-$125 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2653770324","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653770324?lang=en_us&edition=fundamental","pubTime":"2026-07-24 09:34","pubTimestamp":1784856898,"startTime":"0","endTime":"0","summary":"BRIEF-HBM Holdings Expects HY Revenue $120 Million-$125 MillionJuly 24 (Reuters)-Hbm Holdings Ltd2142.HK:EXPECTS REVENUE OF US$120 MILLION-US$125 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026EXPECTS PROFIT OF US$62 MILLION-US$67 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026Further company coverage:2142.HK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43P15F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105113388","title":"HBM Holdings Signals Strong First-Half 2026: Revenue to Rise c.20% to Up to US$125 Million; Profit Seen at US$62-67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1105113388","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105113388?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:25","pubTimestamp":1784852744,"startTime":"0","endTime":"0","summary":"HBM Holdings Limited (HBM) issued a positive profit alert for the six months ended 30 June 2026, projecting revenue between US$120.00 million and US$125.00 million, versus US$101.00 million in the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183012545","title":"HBM Holdings-B (02142) Expects Mid-Year Net Profit Between $62 Million and $67 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1183012545","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1183012545?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:10","pubTimestamp":1784851816,"startTime":"0","endTime":"0","summary":"A profit alert has been issued by HBM Holdings-B (02142). The company released an announcement projecting revenue for the six months ending June 30, 2026, to be in the range of approximately $120...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774076","title":"Press Release: Harbour Biomed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-year as Platform-based Advantages Drive Sustainable Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774076","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774076?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:03","pubTimestamp":1784851380,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced a positive profit alert for the six months ended June 30, 2026 .Based on a preliminary review of the Company's unaudited management accounts for the Reporting Period, the revenue is expected to range between US$120 million  and US$125 million , representing an increase of approximately 19% to 24% compared with approximately US$101 million for the corresponding period in 2025. The profit for the Reporting Period is expected to range between US$62 million  and US$67 million . Total adjusted profit ([1]) is expected to range between US$70 million  and US$75 million .The expected revenue growth and scaled profitability are primarily attributable to:-- Continued strategic collaborations with global multinational","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4113","VTHR","BK4604","BK4555","BK4585","BK1574","BK4099","BK4232","ORR","R","AIPO","BK4022","AGIX","BK1161","CHAT","BK4588","BMS","MSS","BK1583","ARTY","QTOC","03160","TM","02142","CNS","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774037","title":"Hbm Holdings - Expects Revenue of Us$120 Mln-us$125 Mln for Six Months Ended 30 June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774037","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774037?lang=en_us&edition=fundamental","pubTime":"2026-07-24 08:00","pubTimestamp":1784851246,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nFWN43P15F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1161","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653922277","title":"Nona Biosciences Enters Research Collaboration with the Medical University of Vienna to Advance Fully Human Antibody Development for Infectious Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2653922277","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653922277?lang=en_us&edition=fundamental","pubTime":"2026-07-23 08:55","pubTimestamp":1784768151,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA969V9V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02142","BK1574","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653627641","title":"Is HBM Holdings (SEHK:2142) Fully Valued After Its Asthma IND Approval?","url":"https://stock-news.laohu8.com/highlight/detail?id=2653627641","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653627641?lang=en_us&edition=fundamental","pubTime":"2026-07-21 18:16","pubTimestamp":1784629000,"startTime":"0","endTime":"0","summary":"HBM Holdings (SEHK:2142) is in focus after China’s National Medical Products Administration approved the Investigational New Drug application for HBM7575/SKB575, a long-acting bispecific antibody candidate for asthma co-developed with Kelun-Biotech.\nSee our latest analysis for HBM Holdings.\nThe IND approval appears to have reinforced interest in HBM Holdings, with the HK$11.96 share price supported by a 9.72% 1 month share price return and a very large 3 year total shareholder return, even...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2142/hbm-holdings-shares/news/is-hbm-holdings-sehk2142-fully-valued-after-its-asthma-ind-a","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","DRMY","DRMP","IND","BK4168","02142","COPP","DRAM","BK1574","DRAL","MUZ","MULL","BK1161","MIC","BK1583","HBMX","RAM","MUU","BK4588","DISK","HBM","MUYY","MUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651419178","title":"HBM Holdings's Asthma Drug Candidate Secures China's Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2651419178","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651419178?lang=en_us&edition=fundamental","pubTime":"2026-07-16 14:40","pubTimestamp":1784184006,"startTime":"0","endTime":"0","summary":"HBM Holdings (HKG:2142) investigational new drug application for HBM7575, a long-acting bispecific antibody for asthma treatment, has been approved by China's National Medical Products Administration.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","DRAM","BK1574","MULL","02142","06990","LU0196878994.USD","BK4588","BK1583","MUD","RAM","MUU","DRAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124796546","title":"HBM HOLDINGS-B Receives Regulatory Clearance for Asthma Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1124796546","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124796546?lang=en_us&edition=fundamental","pubTime":"2026-07-15 18:06","pubTimestamp":1784109988,"startTime":"0","endTime":"0","summary":"The China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for HBM7575, also known as SKB575.This long-acting bispecific antibody targets...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1583","BK1161","BMED","IBBQ","02142"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.2419},{"period":"1month","weight":0.3478},{"period":"3month","weight":0.2342},{"period":"6month","weight":0.3524},{"period":"1year","weight":0.4041},{"period":"ytd","weight":0.3002}],"compareEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":0.0434},{"period":"3month","weight":-0.0218},{"period":"6month","weight":-0.0441},{"period":"1year","weight":-0.0085},{"period":"ytd","weight":-0.0091}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083377},{"month":2,"riseRate":0.333333,"avgChangeRate":0.000026},{"month":3,"riseRate":0.5,"avgChangeRate":0.051559},{"month":4,"riseRate":0.333333,"avgChangeRate":0.009952},{"month":5,"riseRate":0.5,"avgChangeRate":0.016802},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.072876},{"month":7,"riseRate":0.5,"avgChangeRate":0.053076},{"month":8,"riseRate":0.333333,"avgChangeRate":0.054358},{"month":9,"riseRate":0.4,"avgChangeRate":-0.065735},{"month":10,"riseRate":0,"avgChangeRate":-0.180686},{"month":11,"riseRate":0.8,"avgChangeRate":0.25789},{"month":12,"riseRate":0.6,"avgChangeRate":0.266929}],"exchange":"SEHK","name":"HBM HOLDINGS-B","nameEN":"HBM HOLDINGS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"HBM HOLDINGS-B,02142,HBM HOLDINGS-B股票,HBM HOLDINGS-B股票老虎,HBM HOLDINGS-B股票老虎国际,HBM HOLDINGS-B行情,HBM HOLDINGS-B股票行情,HBM HOLDINGS-B股价,HBM HOLDINGS-B股市,HBM HOLDINGS-B股票价格,HBM HOLDINGS-B股票交易,HBM HOLDINGS-B股票购买,HBM HOLDINGS-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"HBM HOLDINGS-B(02142),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest HBM HOLDINGS-B(02142) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}